The Ultimate Guide to Sauna, Cold Plunges, and Metabolic Health
By Nicholas Ogu
A patient down with flu. Photo: Unsplash.com
The US Food and Drug Administration (FDA) has reversed its decision and agreed to review Moderna's mRNA flu vaccine, marking a significant shift in the regulatory landscape.
The decision comes after the FDA initially refused to accept the application, citing concerns over the trial design.
According to reports, the FDA had told Moderna that its application didn't contain an "adequate and well-controlled" trial because the control arm didn't reflect the "best-available standard of care in the United States".
However, after a constructive Type A meeting, the FDA agreed to review the application, seeking full approval for adults 50 to 64 years of age and accelerated approval for adults 65 and older, along with a post-marketing requirement to conduct an additional study in older adults.
Moderna's vaccine is designed to protect against flu in people ages 50 and older. If approved, it could be available for the 2026-2027 flu season. The company has been working to address the FDA's concerns and has proposed a revised regulatory approach with different pathways by age.
The decision is seen as a positive development for Moderna, which has faced challenges in recent months. The company's stock price rose more than 8% after the announcement.
Analysts have noted that the FDA's reversal is a "meaningful positive" for Moderna, although uncertainty remains.
The FDA's initial refusal had sparked controversy, with some experts questioning whether the decision was merit-based or politically motivated.
The agency has maintained that its decision was based on scientific concerns, but critics argue that the move undermined confidence in the FDA's regulatory process.
Moderna's president, Stephen Hoge, expressed surprise and confusion over the initial decision, noting that the FDA had previously agreed to the study plan. The company's CEO, Stéphane Bancel, welcomed the FDA's decision to review the application, saying it was a "constructive" step forward.
The FDA's decision to review Moderna's vaccine is seen as a significant development in the fight against flu. The mRNA technology used in the vaccine has been hailed as a breakthrough, and its approval could pave the way for more innovative treatments.
The FDA's decision has implications for the broader vaccine industry. If approved, Moderna's vaccine could become a key player in the flu vaccine market. The company is also working on a combination of flu and COVID-19 vaccine, which could be a game-changer for public health.
Comments
Post a Comment